MUT型甲基丙二酸血症基因治疗研究进展

doi:10.12372/jcp.2024.24e0274

Abstract

Abstract:

MUT-type methylmalonic acidemia (MMA) is an autosomal monogenic genetic disorder caused by mutations in the MMUT gene, which can involve multiple organ damage, mainly brain damage, and has a high mortality rate. Diet therapy, levocarnitine and vitamin B₁₂ therapy are the main treatment method for MUT-type MMA, and some severe patients need liver and kidney transplantation, but the treatment effect and prognosis are poor. Gene therapy for MUT-type MMA using various vectors in animal model and phase 1/2 study are underway. Gene therapy in MUT-type MMA clinical trials is still in an early stage and provides a new treatment method. This article reviews the current status of gene therapy research for MUT-type MMA and aims to guide future research.

Key words: methylmalonic acidemia, MMUT gene, gene therapy

Reviewer: DING Yi, YU Yue, Reviser: HAN Lianshu. Research progress in gene therapy for MUT-type methylmalonic acidemia[J].Journal of Clinical Pediatrics, 2024, 42(12): 1051-1055.

References 33

[1]	Acquaviva C, Benoist JF, Pereira S, et al. Molecular basis of methylmalonyl-CoA mutase apoenzyme defect in 40 European patients affected by mut(o) and mut- forms of methylmalonic acidemia: identification of 29 novel mutations in the MUT gene[J]. Hum Mutat, 2005, 25(2): 167-176. pmid: 15643616
[2]	杨艳玲, 韩连书. 单纯型甲基丙二酸尿症饮食治疗与营养管理专家共识[J]. 中国实用儿科杂志, 2018, 33(7): 481-486.
[3]	Jiang YZ, Sun LY. The value of liver transplantation for methylmalonic acidemia[J]. Front Pediatr, 2019, 7: 87.
[4]	High KA, Roncarolo MG. Gene therapy[J]. N Engl J Med, 2019, 381(5): 455-464.
[5]	Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview[J]. J Clin Diagn Res, 2015, 9(1): Ge01- Ge06.
[6]	Chandler RJ, Tsai MS, Dorko K, et al. Adenoviral-mediated correction of methylmalonyl-CoA mutase deficiency in murine fibroblasts and human hepatocytes[J]. BMC Med Genet, 2007, 8: 24. pmid: 17470278
[7]	Peters H, Nefedov M, Sarsero J, et al. A knock-out mouse model for methylmalonic aciduria resulting in neonatal lethality[J]. J Biol Chem, 2003, 278(52): 52909-52913. doi: 10.1074/jbc.M310533200 pmid: 14555645
[8]	Chandler RJ, Venditti CP. Genetic and genomic systems to study methylmalonic acidemia[J]. Mol Genet Metab, 2005, 86(1-2): 34-43. pmid: 16182581
[9]	Chandler RJ, Venditti CP. Adenovirus-mediated gene delivery rescues a neonatal lethal murine model of mut(0) methylmalonic acidemia[J]. Hum Gene Ther, 2008, 19(1): 53-60. doi: 10.1089/hum.2007.0118 pmid: 18052792
[10]	Zhong L, Granelli-Piperno A, Choi Y, et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells[J]. Eur J Immunol, 1999, 29(3): 964-972. pmid: 10092101
[11]	Gao G, Vandenberghe LH, Alvira MR, et al. Clades of adeno-associated viruses are widely disseminated in human tissues[J]. J Virol, 2004, 78(12): 6381-6388. pmid: 15163731
[12]	Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy[J]. Mol Ther, 2006, 14(3): 316-327. doi: 10.1016/j.ymthe.2006.05.009 pmid: 16824801
[13]	Chandler RJ, Venditti CP. Long-term rescue of a lethal murine model of methylmalonic acidemia using adeno-associated viral gene therapy[J]. Mol Ther, 2010, 18(1): 11-16. doi: 10.1038/mt.2009.247 pmid: 19861951
[14]	Carrillo-Carrasco N, Chandler RJ, Chandrasekaran S, et al. Liver-directed recombinant adeno-associated viral gene delivery rescues a lethal mouse model of methylmalonic acidemia and provides long-term phenotypic correction[J]. Hum Gene Ther, 2010, 21(9): 1147-1154. doi: 10.1089/hum.2010.008 pmid: 20486773
[15]	Senac JS, Chandler RJ, Sysol JR, et al. Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery[J]. Gene Ther, 2012, 19(4): 385-391. doi: 10.1038/gt.2011.108 pmid: 21776024
[16]	Chandler RJ, Venditti CP. Pre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA)[J]. Mol Genet Metab, 2012, 107(3): 617-619. doi: 10.1016/j.ymgme.2012.09.019 pmid: 23046887
[17]	Manoli I, Sysol JR, Epping MW, et al. FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia[J]. JCI Insight, 2018, 3(23): e124351.
[18]	Manoli I, Sysol J, Li L, et al. Muscle targeted transgene expression rescues the lethal phenotype of Mut knockout mice[C]. 34th Annual Meeting of the Society-for-Inherited-Metabolic-Disorders. 2011.
[19]	Mingozzi F, High KA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape[J]. Annu Rev Virol, 2017, 4(1): 511-534. doi: 10.1146/annurev-virology-101416-041936 pmid: 28961410
[20]	Chandler RJ, Di Pasquale G, Sloan JL, et al. Systemic gene therapy for methylmalonic acidemia using the novel adeno-associated viral vector 44.9[J]. Mol Ther Methods Clin Dev, 2022, 27: 61-72.
[21]	Kishimoto TK. Development of ImmTOR tolerogenic nanoparticles for the mitigation of anti-drug antibodies[J]. Front Immunol, 2020, 11: 969. doi: 10.3389/fimmu.2020.00969 pmid: 32508839
[22]	Ilyinskii PO, Michaud AM, Rizzo GL, et al. ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia[J]. Mol Ther Methods Clin Dev, 2021, 22: 279-292.
[23]	Marshall H M, Ronen K, Berry C, et al. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting[J]. PLoS One, 2007, 2(12): e1340. doi: 10.1371/journal.pone.0001340 pmid: 18092005
[24]	Wong ES, McIntyre C, Peters HL, et al. Correction of methylmalonic aciduria in vivo using a codon-optimized lentiviral vector[J]. Hum Gene Ther, 2014, 25(6): 529-538. doi: 10.1089/hum.2013.111 pmid: 24568291
[25]	Peters HL, Pitt JJ, Wood LR, et al. Mouse models for methylmalonic aciduria[J]. PLoS One, 2012, 7(7): e40609.
[26]	Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape[J]. Signal Transduct Target Ther, 2021, 6(1): 53.
[27]	罗小平, 应艳琴. 基因编辑与遗传代谢性疾病[J]. 中国儿童保健杂志, 2021, 29(7): 697-700. doi: 10.11852/zgetbjzz2021-0965
[28]	Barzel A, Paulk NK, Shi Y, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice[J]. Nature, 2015, 517(7534): 360-364.
[29]	Chandler RJ, Venturoni LE, Liao J, et al. Promoterless, nuclease-free genome editing confers a growth advantage for corrected hepatocytes in mice with methylmalonic acidemia[J]. Hepatology, 2021, 73(6): 2223-2237.
[30]	An D, Schneller JL, Frassetto A, et al. Systemic messenger RNA therapy as a treatment for methylmalonic acidemia[J]. Cell Rep, 2017, 21(12): 3548-3558. doi: S2211-1247(17)31748-5 pmid: 29262333
[31]	An D, Frassetto A, Jacquinet E, et al. Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia[J]. EBioMedicine, 2019, 45: 519-528. doi: S2352-3964(19)30438-4 pmid: 31303505
[32]	Loughrey D, Dahlman JE. Non-liver mRNA delivery[J]. Acc Chem Res, 2022, 55(1): 13-23.
[33]	Witzigmann D, Kulkarni JA, Leung y, et al. Lipid nanopaticle technology for therapeutic gene regulation in the liverlyl[J]. Ady Drug Deliy Rev, 2020(159): 344-363.

Research progress in gene therapy for MUT-type methylmalonic acidemia

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 33

Related Articles 13

Metrics

Comments

Recommended 0

[1]	CHAI Xingyuan, ZHANG Zhiyong, ZHAO Xiaodong. Progress in radical treatment of X-linked severe combined immunodeficiency [J]. Journal of Clinical Pediatrics, 2024, 42(7): 659-662.
[2]	ZHOU Wenhao. The China Neonatal Genome Project: towards a new future in the treatment of genetic diseases [J]. Journal of Clinical Pediatrics, 2024, 42(5): 379-383.
[3]	CHEN Guoqing, ZHANG Huiwen. Gene therapy for mucopolysaccharidosis type Ⅱ [J]. Journal of Clinical Pediatrics, 2024, 42(3): 270-276.
[4]	JI Taoyun. Prospect of gene therapy for developmental and epileptic encephalopathy [J]. Journal of Clinical Pediatrics, 2023, 41(9): 650-655.
[5]	XI Bixin, HU Qun, LIU Aiguo. Advances in the gene therapy for Fanconi anemia [J]. Journal of Clinical Pediatrics, 2023, 41(2): 156-160.
[6]	FANG Hongjun, YANG Sai, KUANG Xiaojun, JIANG Zhi, ZHOU Zhen, WANG Lijuan, WU Liwen, YANG Liming, LIU Shulei, LIAO Hongmei. Analysis of clinical phenotype and genotype in 171 children with Duchenne muscular dystrophy [J]. Journal of Clinical Pediatrics, 2022, 40(3): 189-195.
[7]	LI Guangxu, PAN Xiang, LU Jun, et al. Clinical and genetic analysis of Imerslund-Gräsbeck syndrome caused by compound heterozygous variation of AMN gene: a case report [J]. Journal of Clinical Pediatrics, 2021, 39(4): 276-.
[8]	OU Hanbing. Progress on treatment of beta-thalassemia major [J]. Journal of Clinical Pediatrics, 2019, 37(2): 153-.
[9]	WEI Jianhua. Recent advances of clinical managements of primary ciliary dyskinesia [J]. Journal of Clinical Pediatrics, 2019, 37(2): 144-.
[10]	LIU Min, CUI Lidan, WANG Qi. Clinical characteristics and gene analysis of critical methylmalonic acidemia in children [J]. Journal of Clinical Pediatrics, 2019, 37(12): 885-.
[11]	ZHANG Lei, JIE Xiaolin, LI Juan, CHAI Xiaojing, ZHU Junfang. Progress on genetics and therapy in the spinal muscular atrophy [J]. , 2017, 35(8): 632-.
[12]	LI fan, QIAO Junying, ZHAO Jianchuang, HUANG Xianjie, WANG Na. Clinical analysis of methylmalonic acidemia in 21 children [J]. , 2017, 35(5): 359-.
[13]	LI Dongxiao, LIU Yupeng, DING Yuan, LI Xiyuan, SONG Jinqing, LI Mengqiu, QIN Yaping, YANG Yanling. A pedigree of a rare Cb1X type X-linked methylmalonic acidemia due to transcriptional co-regulator HCFC1 mutation [J]. , 2016, 34(3): 212-.